FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to a method for the treatment or improvement of the condition with muscular weakness in a human patient suffering from muscular weakness or with a tendency to its occurrence. The method for the treatment or improvement of the condition with muscular weakness in a human patient suffering from muscular weakness or with a tendency to its occurrence includes injection to the specified patient of therapeutically effective amount of alkaline phosphatase, which is at least 95% identical to SEQ ID NO:1, where the patient has an increased concentration of pyrophosphate (PPi), and where the patient: has not previously been diagnosed with hypophosphatasia (hereinafter – HPP); has HPP and no other symptoms related to HPP; or has not HPP and has muscular weakness or a tendency to its development.
EFFECT: above-described method for the treatment allows for reduction of pyrophosphate concentration and effective treatment or improvement of the condition with muscular weakness in a human patient.
49 cl, 4 tbl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| AFRICAN SWINE FEVER VACCINE | 2020 |
|
RU2819672C2 |
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| ANTIGENIC POLYPEPTIDES BASED ON OSPA SEQUENCE | 2019 |
|
RU2816208C2 |
| OPTIONS FOR H-BINDING PROTEIN FACTOR AND METHODS OF THEIR USE | 2015 |
|
RU2811942C2 |
